

Biotech Daily



Wednesday August 29, 2018

Daily news on ASX-listed biotechnology companies

ANATARA LIFESCIENCES

Anatara says it has appointed Sue MacLeman and Dr Jane Ryan as non-executive chair and non-executive director, respectively, from September 1, 2018.

Anatara said Ms MacLeman would replace Dr Jay Hetzel who had been interim chairman since the retirement of co-founder Dr Mel Bridges earlier this year (BD: May 17, 2018). The company said that following the decision “to focus on the development of products and technologies in the human health sector ... [it had] undertaken an extensive search to identify new directors with the relevant background and experience which has resulted in these appointments”.

Anatara said that Ms MacLeman had more than 25 years’ experience as a pharmaceutical, biotechnology and medical technology executive with senior roles at Schering-Plough Corporation, now Merck, Amgen, Bristol-Myers Squibb and Mesoblast. The company said that Ms MacLeman recently retired as the Medical Technologies and Pharmaceuticals Growth Centre, or MTP Connect, chief executive officer and move to non-executive chairman later this year.

Anatara said that previously Ms MacLeman was the chief executive officer of Eqitx, Benitec and Progen, a current director of Oventus and was formerly a director of the Adelaide-based RHS or Reproductive Health Science.

The company said Ms MacLeman had experience in commercialization, strategic planning, capital markets, fund raising, mergers and acquisitions and alliance management.

Anatara said that Dr Ryan has more than 25 years’ experience in the pharmaceutical and biotechnology industries, had managed research and development programs and held roles in business development and alliance management.

The company said that previously Dr Ryan had worked for Peptech, later Arana, now Teva Australia, Roche, Cambridge Antibody Technology and Biota and had led fundraising campaigns including the awarding of Biota’s \$US230 million BARDA contract. Anatara said that director Paul Grujic would retire on August 31 and Dr Hetzel would retire at the annual general meeting in November 2018, with Iain Ross and acting chief executive officer Dr Tracie Ramsdale continuing as directors.

The company said that a search was underway for a new chief executive officer. Anatara said it had appointed Sydney’s Peloton Capital as a corporate advisor issuing the company 750,000 options exercisable at \$1.45 each by December 14, 2020. Anatara was up three cents or 5.3 percent to 60 cents.

**Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily**